Damora Therapeutics, Inc.

NASDAQ:DMRA

Biotechnology

Healthcare
$22.98 +0.34%

+$0.07 today

Market cap
$1.42B
Beta
1.48
P/E (TTM)
-0.1
EPS (TTM)
-$177.15
52W Low $2.45High $38.33

Volume 0.58M

Average 0.33M

DMRA Operating Cash Flow

Cash generated by the company's core business operations during the period.

Damora Therapeutics, Inc.NASDAQ: DMRA

Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Operating cash flow of -$20.6M in Q1 FY2026

Q1 FY2026 operating cash flow was -$20.6M. Trailing-twelve-month operating cash flow was -$29.96M. Over 3 fiscal years it compounded at -46.1% a year.

Context

  • Operating cash flow grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly operating cash flow holds near -$20.6M or moves back toward the trailing-twelve-month quarterly average of -$7.49M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$20.6M-3739.2% QoQ
Last fiscal yearDec 2025
-$6.73M-63.9% YoY
LTMJun 2024
-$29.96M-21.7% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-63.9%——
3-year CAGR-46.1%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
(6.73M) USD
Year-over-year change
+63.9%

Operating Cash Flow vs competitors

How DMRA compares with its peers on the latest reported figures

  • DMRA's LTM Jun 2024 operating cash flow of $29.96M is the smallest of the 9 companies compared; the peer median is $59.34M.
  • Over three fiscal years its annual growth of -46.1% compares with a peer median of +7.1%.
DMRA Competitors Peer median
Operating Cash Flow for DMRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCYIncyte CorporationLTM Jun 2026$1.98B +97.4%+13.4%34.0%
GMABGenmab A/SLTM Jun 2026$890.35M —-32.8%21.6%
IRONDisc Medicine, Inc.LTM Sep 2026$189.94M +15.3%+62.2%—
QUREuniQure N.V.LTM Mar 2026$172.11M +3.5%+7.1%951.2%
GERNGeron CorporationLTM Mar 2026$125.96M -38.4%-4.5%64.2%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$79.27M +122.7%—26.4%
COAGHemab Therapeutics Holdings, Inc. Common StockFY2025$61.48M ———
KROSKeros Therapeutics, Inc.LTM Mar 2026$57.2M -227.5%—172.4%
DMRADamora Therapeutics, Inc.LTM Jun 2024$29.96M —-46.1%—
Peer median (excluding DMRA) $59.34M+9.4%+7.1%49.1%

Competitors are the stored peer set for DMRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(51.75M)(61.62M)(38.35M)(21.44M)(209.84M)
Depreciation & Amortization441K490K830K181K34K
Deferred Income Tax00000
Stock-Based Compensation0000998K
Change in Working Capital(6.62M)11.94M(4.37M)(2.67M)18.36M
Accounts Receivables00000
Inventory00000
Accounts Payables(1.32M)1.82M(1.65M)(1.33M)17.27M
Other Working Capital(5.3M)10.12M(2.72M)(1.34M)1.09M
Other Non-Cash Items5.63M6.27M4.98M5.3M183.72M
Operating Cash Flow(52.31M)(42.93M)(36.91M)(18.62M)(6.73M)
Capital Expenditures(223K)(196K)000
Acquisitions (Net)0083K0(17.37M)
Purchases of Investments(84.21M)(44.87M)(25.94M)00
Sales of Investments36.38M57.45M48.18M11.65M0
Other Investing Activities00000
Investing Cash Flow(48.05M)12.38M22.33M11.65M(17.37M)
Debt Repayment00000
Common Stock Issued0507K2.88M00
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities000033K
Financing Cash Flow0507K2.88M0266.84M
Effect of Forex Changes(663K)264K384K(317K)705K
Net Change in Cash(101.02M)(29.78M)(11.32M)(7.29M)243.45M
Free Cash Flow(52.53M)(43.13M)(36.91M)(18.62M)(6.73M)

Damora Therapeutics, Inc.

NASDAQ:DMRA

Intrinsic Alpha fair value

Locked

Current Price

$22.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.